Crinetics Pharmaceuticals (CRNX) Gets Initiated With a Hold Rating at Goldman Sachs

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is one of the best oversold NASDAQ stocks to buy now. In a report released on July 10, Richard Law CFA from Goldman Sachs initiated coverage of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) with a Hold rating and a $36 price target.

Is Crinetics Pharmaceuticals Inc. (CRNX) the Worst Performing Mid Cap Stock to Buy According to Analysts?

A doctor and a patient discussing the success of the clinical trial for a new nonpeptide somatostatin receptor agonist.

The analyst told investors that Crinetics Pharmaceuticals, Inc.’s (NASDAQ:CRNX) near-term value may be considerably influenced by uncertainties, such as the launch performances of paltusotine and Crenessity. He further reasoned that Crinetics Pharmaceuticals, Inc.’s (NASDAQ:CRNX) lack of other meaningful pipeline catalysts supports the Neutral rating.

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is a clinical-stage pharmaceutical company that develops and commercializes novel therapeutics for rare endocrine diseases and endocrine-related tumors.

The company’s product candidate, CRN00808, is an oral treatment for acromegaly. It is also developing other oral treatments for neuroendocrine tumors, hyperinsulinism, and Cushing’s disease.

While we acknowledge the potential of CRNX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than XXXX and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.